WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. today announced that its partner BeiGene has dosed the first five patients in its first-in-human Phase 1 trial to evaluate BG-68501, a small ...

- ETX-636 preclinical data to be presented at the AACR annual meeting, showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα Mutant PI3Kα is a key and ...

Enzymes that drive cancer growth are already addressed by several drugs, but there’s still room to improve and expand this approach. BeiGene sees opportunity in the lead program of Ensem Therapeutics ...

- ETX-636 advanced to the clinic following preclinical observations showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα WALTHAM, Mass., July 01, 2025 ...

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & WALTHAM, Mass.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology ...

(MENAFN- PR Newswire) WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the ...

Ensem Therapeutics, Inc announced that its partner BeiGene has dosed the first five patients in its first-in-human phase 1 trial to evaluate BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) ...

People enter a building of biotechnology firm BeiGene Ltd at the Suzhou Industrial Park in Suzhou (Reuters) -BeiGene said on Tuesday it would buy the global license for a cancer therapy that is ready ...

Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The ...

"Dr. Kutok is a seasoned executive with the right credentials to guide ENSEM's science into the future," stated Shengfang Jin, Ph.D., President & Chief Executive Officer of ENSEM. "We are excited to ...